These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 32198274)

  • 21. [Effects of two treatment regimens for drug-resistant tuberculosis in tuberculosis control project areas: a comparative study].
    Li L; Zheng SH; Chu NH; Xie YG; Yang YZ; Li Q; Wang XM; Yan XL; Tan WG; Miao ZP; Duanmu HJ
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3387-91. PubMed ID: 19159566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Advances in chemotherapy of multidrug-resistant and rifampicin-resistant tuberculosis].
    Liu SS; Wang LZ; Tang SJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Apr; 43(4):371-375. PubMed ID: 32294820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis.
    Rieder HL; Van Deun A
    Int J Tuberc Lung Dis; 2017 Jan; 21(1):123-124. PubMed ID: 28157478
    [No Abstract]   [Full Text] [Related]  

  • 24. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.
    Lange C; Duarte R; Fréchet-Jachym M; Guenther G; Guglielmetti L; Olaru ID; Oliveira O; Rumetshofer R; Veziris N; van Leth F;
    Am J Respir Crit Care Med; 2016 Oct; 194(8):1029-1031. PubMed ID: 27685538
    [No Abstract]   [Full Text] [Related]  

  • 25. Rapid and accurate detection of rifampin and isoniazid-resistant Mycobacterium tuberculosis using an oligonucleotide array.
    Huang WL; Hsu ZJ; Chang TC; Jou R
    Clin Microbiol Infect; 2014 Sep; 20(9):O542-9. PubMed ID: 24372766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.
    Varaine F; Guglielmetti L; Huerga H; Bonnet M; Kiria N; Sitienei JK; Rich M; Mitnick CD
    Am J Respir Crit Care Med; 2016 Oct; 194(8):1028-1029. PubMed ID: 27739887
    [No Abstract]   [Full Text] [Related]  

  • 27. Epidemiology, control and treatment of multidrug-resistant tuberculosis.
    Chaulet P; Raviglione M; Bustreo F
    Drugs; 1996; 52 Suppl 2():103-7; discussion 107-8. PubMed ID: 8869846
    [No Abstract]   [Full Text] [Related]  

  • 28. [Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results].
    Fujino T; Hasegawa N; Satou R; Komatsu H; Kawada K
    Kekkaku; 1998 Jul; 73(7):471-6. PubMed ID: 9739579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap.
    Nunn A; Tweed C
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1418-1419. PubMed ID: 27725060
    [No Abstract]   [Full Text] [Related]  

  • 30. Bedaquiline or delamanid for rifampin-resistant tuberculosis?
    Lessem E; Cox V; Furin J
    Lancet Respir Med; 2017 Oct; 5(10):772-774. PubMed ID: 28887015
    [No Abstract]   [Full Text] [Related]  

  • 31. Rifampicin-resistant tuberculosis: what is the best initial empiric regimen in Mumbai, India?
    Mullerpattan JB; Nikam C; Sharma U; Rodrigues C; Pinto LM
    Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28729472
    [No Abstract]   [Full Text] [Related]  

  • 32. [Brief discussion on grouping of antituberculosis drugs for treating multidrug- and rifampicin-resistant tuberculosis 2018 update].
    Yao L; Tang SJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 May; 42(5):329-332. PubMed ID: 31137108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time to review treatment of isoniazid-resistant tuberculosis?
    D'Ambrosio L; Migliori GB; Sotgiu G
    Lancet Infect Dis; 2017 Feb; 17(2):127-128. PubMed ID: 27865889
    [No Abstract]   [Full Text] [Related]  

  • 34. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidrug-resistant tuberculosis--can the tide be turned?
    Zumla A; Grange JM
    Lancet Infect Dis; 2001 Oct; 1(3):199-202. PubMed ID: 11871496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic choices in rifampicin-resistant tuberculosis.
    Ganatra S; Udwadia Z; Rodrigues C
    Lancet Infect Dis; 2016 Nov; 16(11):1220-1221. PubMed ID: 27788974
    [No Abstract]   [Full Text] [Related]  

  • 37. Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009-2016.
    Mustazzolu A; Borroni E; Cirillo DM; Giannoni F; Iacobino A; ; Fattorini L
    Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29724919
    [No Abstract]   [Full Text] [Related]  

  • 38. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The treatment of multidrug-resistant tuberculosis in Turkey.
    Tahaoğlu K; Törün T; Sevim T; Ataç G; Kir A; Karasulu L; Ozmen I; Kapakli N
    N Engl J Med; 2001 Jul; 345(3):170-4. PubMed ID: 11463011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Joint Statement on the New WHO Recommendations for Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis].
    Maurer FP; Bauer T; Diel R; Häcker B; Lange C; Niemann S; Otto-Knapp R; Schönfeld N
    Pneumologie; 2019 May; 73(5):270-273. PubMed ID: 31083750
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.